Cannabionoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas

Cristina Blázquez,1 Luis González-Feria,4 Luis Álvarez,2 Amador Haro,1 M. Llanos Casanova,3 and Manuel Guzmán1

1Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University; 2Research Unit, La Paz University Hospital; 3Project on Cellular and Molecular Biology and Gene Therapy, Ciemat, Madrid, Spain; and 4Department of Neurosurgery, University Hospital, Tenerife, Spain

ABSTRACT

Cannabinoids inhibit tumor angiogenesis in mice, but the mechanism of their antiangiogenic action is still unknown. Because the vascular endothelial growth factor (VEGF) pathway plays a critical role in tumor angiogenesis, here we studied whether cannabinoids affect it. As a first approach, cDNA array analysis showed that cannabinoid administration to mice bearing s.c. gliomas lowered the expression of various VEGF pathway-related genes. The use of other methods (ELISA, Western blotting, and confocal microscopy) provided additional evidence that cannabinoids depressed the VEGF pathway by decreasing the production of VEGF and the activation of VEGF receptor (VEGFR)-2, the most prominent VEGF receptor, in cultured glioma cells and in mouse gliomas. Cannabinoid-induced inhibition of VEGF production and VEGFR-2 activation was abrogated both in vitro and in vivo by pharmacological blockade of ceramide biosynthesis. These changes in the VEGF pathway were paralleled by changes in tumor size. Moreover, intratumoral administration of the cannabinoid Δ9-tetrahydrocannabinol to two patients with glioblastoma multiforme (grade IV astrocytoma) decreased VEGF levels and VEGFR-2 activation in the tumors. Because blockade of the VEGF pathway constitutes one of the most promising antitumoral approaches currently available, the present findings provide a novel pharmacological target for cannabinoid-based therapies.

INTRODUCTION

To grow beyond minimal size, tumors must generate a new vascular supply for purposes of gas exchange, cell nutrition, and waste disposal (1–4). They do so by secreting proangiogenic cytokines that promote the formation of blood vessels. Vascular endothelial growth factor (VEGF; also known as VEGF-A) is considered the most important proangiogenic molecule because it is expressed abundantly by a wide variety of animal and human tumors and because of its potency, selectivity, and ability to regulate most and perhaps all of the steps in the angiogenic cascade (1–4). The best characterized VEGF receptors are two related receptor tyrosine kinases termed VEGF receptor (VEGFR)-1 (also known as Flt-1) and VEGFR-2 (also known as kinase domain region or Flk-1). Although VEGF binds to VEGFR-1 with higher affinity, numerous studies in cultured cells and laboratory animals have provided evidence that VEGFR-2 is the major mediator of the mitogenic, antiapoptotic, angiogenic, and permeability-enhancing effects of VEGF (1–4). Because overexpression of VEGF and VEGFR-2 is causally involved in the progression of many solid tumors, several strategies to inhibit VEGF signaling have been translated into clinical trials in cancer patients, including anti-VEGF and anti-VEGFR-2 antibodies, small VEGFR-2 inhibitors, and a soluble decoy VEGFR (5–8). In addition, clinical trials are being performed with a number of promising anticancer compounds such as Iressa and Herceptin that block proteins involved in the induction of the VEGF pathway (5–8).

Cannabinoids. The active components of Cannabis sativa L. (marijuana), and their derivatives exert a wide array of effects by activating their specific G protein-coupled receptors CB1 and CB2, which are normally engaged by a family of endogenous ligands—the endocannabinoids (9, 10). Marijuana and its derivatives have been used in medicine for many centuries, and there is currently a renaissance in the study of the therapeutic effects of cannabinoids. Today, cannabinoids are approved to palliate the wasting and emesis associated with cancer and AIDS chemotherapy (11), and ongoing clinical trials are determining whether cannabinoids are effective agents in the treatment of pain (12), neurodegenerative disorders such as multiple sclerosis (13), and traumatic brain injury (14). In addition, cannabinoid administration to mice and/or rats induces the regression of lung adenocarcinomas (15), gliomas (16), thyroid epitheliomas (17), lymphomas (18), and skin carcinomas (19). These studies have also evidenced that cannabinoids display a fair drug safety profile and do not produce the generalized cytotoxic effects of conventional chemotherapies, making them potential antitumoral agents (20, 21).

Little is known, however, about the mechanism of cannabinoid antitumoral action in vivo. By modulating key cell signaling pathways, cannabinoids directly induce apoptosis or cell cycle arrest in different transformed cells in vitro (20). However, the involvement of these events in their antitumoral action in vivo is as yet unknown. More recently, immunohistochemical and functional analyses of the vasculature of gliomas (22) and skin carcinomas (19) have shown that cannabinoid administration to mice inhibits tumor angiogenesis. These findings prompted us to explore the mechanism by which cannabinoids impair angiogenesis of gliomas and, particularly, the possible impact of cannabinoids on the VEGF pathway. Here, we report that cannabinoid administration inhibits the VEGF pathway in cultured glioma cells, in glioma-bearing mice, and in two patients with glioblastoma multiforme. In addition, this effect may be mediated by ceramide, a sphingolipid second messenger implicated previously in cannabinoid signaling in glioma cells (23).

MATERIALS AND METHODS

Cannabinoids. The Δ9-tetrahydrocannabinol was kindly given by Alfredo Dupetit (The Health Concept, Richelbach, Germany). JWH-133 was kindly given by Dr. John Huffman (Department of Chemistry, Clemson University, Clemson, SC; Ref. 24). WIN-55,212-2 and anandamide were from Sigma (St. Louis, MO). SR141716 and SR144528 were kindly given by Sanofi-Synthelabo (Montpellier, France). For in vitro incubations, cannabinoid agonists and antagonists were directly applied at a final DMEM concentration of 0.1–0.2% (v/v). For in vivo experiments, ligands were prepared at 1% (v/v) DMSO in 100 μl PBS supplemented with 5 mg/ml BSA. No significant influence of the vehicle was observed on any of the parameters determined.

Cell Culture. The rat C6 glioma (25), the human U373 MG astrocytoma (25), the mouse PDV.C57 epidermal carcinoma (19), and the human ECV304 bladder cancer epithelioma (22) were cultured as described previously. Human glioma cells were prepared from a glioblastoma multiforme (grade IV astrocytoma; Ref. 26). The biopsy was digested with collagenase (type Ia; Sigma) and fetal bovine serum, and the resulting single cell suspension was centrifuged. Cells were then cultured in DMEM at 37°C for 90 min, the supernatant was seeded in DMEM containing 15% FCS and 1 mM glutamine, cells were grown for 2 passages, and 24 h before the experiments, cells were transferred to 0.5%-serum DMEM. Cell viability was determined by trypan blue exclusion. Rat recombinant VEGF and N-acetylsphingosine (C2-ceramide) were from Sigma.

Received 12/16/03; revised 4/1/04; accepted 6/10/04.
Grant support: Fundación Científica de la Asociación Española Contra el Cáncer and Ministerio de Ciencia y Tecnología Grant SAF2003-00745.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Manuel Guzmán, Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain. Phone: 34-913944688; Fax: 34-913944672; E-mail: mvg@bbm1.ucm.es.
Tumor Induction in Mice. Tumors were induced in mice deficient in recombination activating gene 2 by s.c. flank inoculation of \(5 \times 10^5\) C6 glioma cells in 100 l PBS supplemented with 0.1% glucose (16). When tumors had reached a volume of 350–450 mm\(^3\), animals were assigned randomly to the various groups and injected intratumorally for up to 8 days with 50 \(\mu\)g/day JW-133 and/or 60 \(\mu\)g/day fumonisin B1 (Alexis, San Diego, CA). Control animals were injected with vehicle. Tumors were measured with external caliper, and volume was calculated as \((4/3)\pi \times (width/2)^2 \times (length/2)\).

Human Tumor Samples. Tumor biopsies were obtained from two of the patients enrolled in an ongoing Phase II/I clinical trial (at the Neurosurgery Department of Tenerife University Hospital, Spain) aimed at investigating the effect of \(\Delta^2\)-tetrahydrocannabinol administration on the growth of recurrent glioblastoma multiforme. The patients had failed standard therapy, which included surgery, radiotherapy (60 Gy), and temozolomide chemotherapy (4 cycles). Patients had clear evidence of tumor progression on sequential magnetic resonance scanning before enrollment in the study, had received no anticancer therapy for \(\geq 1\) year, and had a fair health status (Karnofsky performance score >= 90). The patients provided written informed consent. The protocol was approved by the Clinical Trials Committee of Tenerife University Hospital and by the Spanish Ministry of Health.

Patient 1 (a 48-year-old man) had a right-occipital-lobe tumor (7.5 \(\times\) 6 cm maximum diameters), and Patient 2 (a 57-year-old man) had a right-temporal-lobe tumor (6 \(\times\) 5 cm maximum diameters). Both tumors were diagnosed by the Pathology Department of Tenerife University Hospital as glioblastoma multiforme and showed the hallmarks of this type of tumor (high vascularization, necrotic areas, abundant palisading and mitotic cells, and so on). The tumors were removed extensively by surgery, biopsies were taken, and the tip (\(-5\) cm) of a silastic infusion catheter (9.6 French; 3.2 mm diameter) was placed into the resection cavity. The infusion catheter was connected to a Nutrigradiv subcutaneous infusion reservoir. Each day 0.5–1.5 (median 1.0) mg of \(\Delta^2\)-tetrahydrocannabinol (100 \(\mu\)g/\(\mu\)l in ethanol solution) were dissolved in 30 ml of physiological saline solution supplemented with 0.5% (v/v) human serum albumin, and the resulting solution was filtered and subsequently administered at a rate of 0.3 ml/min with a syringe pump connected to the s.c. reservoir. Patient 1 started the treatment 4 days after the surgery and received a total amount of 24.5 mg of \(\Delta^2\)-tetrahydrocannabinol for 19 days. The posttreatment biopsy was taken 19 days after the cessation of \(\Delta^2\)-tetrahydrocannabinol administration. Patient 2 started the treatment 4 days after the surgery and received a total amount of 13.5 mg of \(\Delta^2\)-tetrahydrocannabinol for 16 days. The posttreatment biopsy was taken 43 days after the cessation of \(\Delta^2\)-tetrahydrocannabinol administration.

RESULTS

1. **Changes in Gene Expression Profile in Mouse Gliomas.** The cDNA array analysis was used as a first approach to test whether cannabinoid administration affects the VEGF pathway in mouse gliomas. Because cannabinoid-based therapeutic strategies should be as devoid as possible of psychotropic side effects and glioma cells express functional CB\(_1\) receptors, which do not mediate psychoactivity (16, 26), mice bearing s.c. gliomas were injected with the selective CB\(_1\) agonist JWH-133 (26).

A total of 267 genes related to angiogenesis, hypoxia (perhaps the most potent stimulus for the onset of tumor angiogenesis), and metastasis (a characteristic of actively growing tumors related closely to angiogenesis) were analyzed, of which 126 were considered to be expressed in reliable amounts. JWH-133 administration altered the expression of 10 genes, all of which are directly or indirectly related to the VEGF pathway (Fig. 1). Thus, cannabinoid treatment lowered the expression of the following: (a) VEGF-A [confirming our previous Northern blot data (22)] and its relative VEGF-B (3, 4); (b) hypoxia-inducible factor-1\(\alpha\) [one of the subunits of hypoxia-inducible factor-1, the major transcription factor involved in VEGF gene expression (29)]; (c) two genes known to be under the control of VEGF, namely those encoding connective tissue growth factor [a mitogen involved in extracellular matrix production and angiogenesis (30)], and heme oxygenase-1 [an enzyme highly expressed during hypoxia and inflammation (31)]; and (d) four genes known to encode proteins functionally related to VEGF, namely Id3 [a transcription factor inhibitor involved in angiogenesis and tumor progression (32)], midkine [a proangiogenic and tumorigogenic growth factor (33)], angiotopi-
etin-2 [a prominent proangiogenic factor that cooperates with VEGF (3, 19, 22)], and Tie-1 [an angiopoietin receptor (34)]. In addition, cannabinoid treatment increased the expression of the gene encoding type I procollagen (H9251 chain) (a metalloproteinase substrate related to matrix remodeling during angiogenesis; Ref. 35).

**Inhibition of VEGF Production in Cultured Glioma Cells and in Mouse Gliomas.**

We focused next on the two main components of the VEGF pathway, namely VEGF and VEGFR-2, in both cultured glioma cells and gliomas in vivo. Incubation of C6 glioma cells with the synthetic cannabinoid WIN-55,212-2 (100 nM), a mixed CB1/CB2 receptor agonist, significantly reduced VEGF production (Fig. 2A). Similarly, U373 MG astrocytoma cells, PDV.C57 epidermal carcinoma cells, and ECV304 bladder carcinoma cells showed a decrease in VEGF levels when treated with WIN-55,212-2 (Fig. 2B). Moreover, C6 glioma cells were cultured for 48 h with vehicle (Control), 100 nM WIN-55,212-2 (WIN), 1 μM C2-ceramide (CER), and/or 0.5 μM fumonisin B1 (FB1), and VEGF levels in the medium were determined (n = 4). Animals bearing gliomas were treated with either vehicle (Control), JWH-133 (JWH), fumonisin B1 (FB1), or JWH-133 plus fumonisin B1 for 8 days as described in “Materials and Methods,” and VEGF levels in the tumors were determined (n = 4–6 for each experimental group). Significantly different (*, P < 0.01; **, P < 0.05) from control incubations or control animals. Bars, ±SD.
Production was tested by the use of involvement of ceramide in cannabinoid-induced inhibition of VEGF CB receptors in cannabinoid-induced inhibition of VEGF production. Interestingly, on cannabinoid exposure the receptor seemed to be B/H11006 fumonisin B1, 86/H9262 antagonist SR141716 (0.5/H9262 B epithelioma ECV304 (Fig. 2). The cannabinoid effect was also observed in the mouse skin carcinoma PDV.C57 and in the human bladder cancer epithelioma ECV304 (Fig. 2B).

To prove the specificity of WIN-55,212-2 action on VEGF release, we used other cannabinoid receptor agonists as well as selective cannabinoid receptor antagonists (Fig. 2C). The inhibitory effect of WIN-55,212-2 was mimicked by the endocannabinoid anandamide (2 μM), another mixed CB1/CB2 agonist, and by the synthetic cannabinoid JWH-133 (100 nM), a selective CB2 agonist. In addition, the CB1 antagonist SR141716 (0.5 μM) and the CB2 antagonist SR144528 (0.5 μM) prevented WIN-55,212-2 action, pointing to the involvement of CB receptors in cannabinoid-induced inhibition of VEGF production.

The sphingolipid messenger ceramide has been implicated in the regulation of tumor cell function by cannabinoids (16, 23, 36). The involvement of ceramide in cannabinoid-induced inhibition of VEGF production was tested by the use of N-acetylphosphoserine (C2-ceramide), a cell-permeable ceramide analog, and fumonisin B1, a selective inhibitor of ceramide synthesis de novo. In line with our previous data in primary cultures of rat astrocytes (28), fumonisin B1 was able to prevent cannabinoid-induced ceramide biosynthesis (relative values of [14C]serine incorporation into ceramide, n = 3: vehicle, 100; 100 nM WIN-55,212-2, 140 ± 1; 100 nM WIN-55,212-2 plus 0.5 μM fumonisin B1, 86 ± 9). C2-ceramide (1 μM) depressed VEGF production, whereas pharmacological blockade of ceramide synthesis de novo with fumonisin B1 (0.5 μM) prevented the inhibitory effect of WIN-55,212-2 (Fig. 2D). We subsequently evaluated whether fumonisin B1 action was also evident in vivo. The decrease in tumor VEGF levels induced by cannabinoid administration (19, 22, 37) was prevented by cotreatment of the animals with fumonisin B1 (Fig. 2E).

Inhibition of VEGFR-2 in Cultured Glioma Cells and in Mouse Gliomas. VEGFR-2 activation was determined by measuring the extent of phosphorylation of two of its essential tyrosine autophosphorylation residues, namely 996 and 1214 (3, 4). Western blot experiments showed that C6 glioma cells express highly phosphorylated VEGFR-2 in the absence of ligand, indicating that the receptor may be constitutively active. Incubation of C6 glioma cells with WIN-55,212-2 or JWH-133 decreased VEGFR-2 activation without affecting total VEGFR-2 levels (Fig. 3A). Confocal microscopy experiments confirmed the decrease in VEGFR-2 immunoreactivity by cannabinoid challenge when fluorescence was expressed per cell nucleus (Fig. 3B) or per total-VEGFR-2 fluorescence (data not shown). Moreover, fumonisin B1 prevented cannabinoid inhibitory action, and C2-ceramide reduced VEGFR-2 activation (Fig. 3C). Interestingly, on cannabinoid exposure the receptor seemed to be preferentially condensed in the perinuclear region, and this relocation was prevented by fumonisin B1 (Fig. 3B). The functional impact of VEGF on C6 glioma cells was supported by the finding that VEGF induced a prosurvival action by preventing the loss of cell viability on prolonged (72 h) cannabinoid or C2-ceramide challenge (Fig. 3E).

The effect of cannabinoid administration on VEGFR-2 activation was subsequently tested in tumor-bearing mice. The ceramide-dependent cannabinoid-induced inhibition of VEGFR-2 activation found in cultured cells was also observed by Western blot (Fig. 4A) and confocal microscopy (Fig. 4B) in mouse gliomas. Like in the cultured-cell experiments and in line with the cDNA array experiments (data not shown), total VEGFR-2 expression in the tumors was unaffected by cannabinoid treatment (Fig. 4, A and B).

Phosphorylated VEGFR-2 has been found previously in the cell nucleus, and it has been postulated that this translocation process might play a role in VEGFR-2 signaling (38–40). However, by confocal microscopy, we found a rather variable fraction of phosphorylated VEGFR-2 in the nuclei of C6 glioma cells in culture and on inoculation in mice, and this fraction of nuclear VEGFR-2 was unaffected after treatment with cannabinoids and/or fumonisin B1 in vitro and in vivo (data not shown).
Changes in the Size of Mouse Gliomas. To test whether the aforementioned ceramide-dependent changes in the VEGF pathway are functionally relevant, we measured tumor size along cannabinoid and fumonisin B1 treatment. In agreement with previous observations (26), JWH-133 administration blocked the growth of s.c. gliomas in mice. Of importance, cotreatment of the animals with fumonisin B1 prevented cannabinoid antitumoral action (Fig. 5).

Inhibition of the VEGF Pathway in Two Patients with Glioblastoma Multiforme. To obtain additional support for the potential therapeutic implication of cannabinoid-induced inhibition of the VEGF pathway, we analyzed the tumors of two patients enrolled in a clinical trial aimed at investigating the effect of Δ9-tetrahydrocannabinol, a mixed CB1/CB2 agonist, on recurrent glioblastoma multiforme. The patients were subjected to local Δ9-tetrahydrocannabinol administration, and biopsies were taken before and after the treatment. In both patients, VEGF levels in tumor extracts were lower after cannabinoid inoculation (Fig. 6A). The Δ9-tetrahydrocannabinol also lowered the expression of phosphorylated VEGFR-2 in the tumors of the two patients, and this was accompanied (in contrast to the mouse glioma experiments shown above) by a decrease in total VEGFR-2 levels (Fig. 6B). This was confirmed by Western blot analysis in Patient 1 (Fig. 6C). Unfortunately, we were unable to obtain appropriate samples for Western blot from Patient 2.

DISCUSSION

Angiogenesis is a prerequisite for the progression of most solid tumors. In particular, gliomas first acquire their blood supply by co-opting existing normal brain vessels to form a well-vascularized tumor mass without the necessity to initiate angiogenesis (41–43). When gliomas progress, they become hypoxic as the co-opted vasculature regresses and malignant cells rapidly proliferate. These hypoxic conditions, in turn, induce robust angiogenesis via the VEGF pathway and angiopoietin-2, and in fact, this angiogenic sprouting distinguishes a grade IV astrocytoma (glioblastoma multiforme) from lower-grade astrocytomas (41–43). Here, we show that cannabinoid treatment impairs the VEGF pathway in mouse gliomas by blunting VEGF production and signaling. Cannabinoid-induced inhibition of VEGF expression and VEGF-2 activation also occurred in cultured glioma cells, indicating that the changes observed in vivo may reflect the direct impact of cannabinoids on tumor cells. Moreover, a depression of the VEGF pathway was also evident in two patients with glioblastoma multiforme. Although the changes in VEGF-2 expression observed in these two patients

Fig. 5. Changes in the size of mouse gliomas after cannabinoid and fumonisin B1 treatment. Animals bearing gliomas (n = 4–6 for each experimental group) were treated with either vehicle (Control, ○), JWH-133 (JWH, ●), fumonisin B1 (FB1, □), or JWH-133 plus fumonisin B1 (JWH + FB1, ◊) for up to 8 days as described in “Materials and Methods.” Examples of formaldehyde-fixed dissected tumors after 8 days of treatment are shown. Bars, ±SD.
do not fully mirror the cultured-cell and mouse data, they clearly follow the same direction. The molecular basis of this discrepancy is, however, unknown.

Our observations do not exclude that cannabinoids may also blunt tumor VEGF signaling indirectly by targeting other receptor-mediated processes that stimulate the VEGF pathway. For example, it is known that engagement of epidermal growth factor (44) and nerve growth factor (45) receptors induces the VEGF pathway, and cannabinoids have been reported to inhibit the epidermal growth factor receptor in skin carcinoma (19) and prostate carcinoma cells (46) as well as the TrkA neurotrophin receptor in breast carcinoma (47) and pheochromocytoma cells (20). However, the molecular mechanisms by which cannabinoid receptor activation impact these growth factor receptors remain obscure.

Recent work has shown that cannabinoids can modulate sphingolipid-metabolizing pathways by increasing the intracellular levels of ceramide (23), a lipid second messenger that controls cell fate in different systems (48, 49). After cannabinoid receptor activation, two peaks of ceramide generation are observed in glioma cells that have different mechanistic origin: (a) the first peak comes from sphingomyelin hydrolysis (50); and (b) the second peak originates from ceramide synthesis de novo (36). The findings reported here expand the role of de novo-synthesized ceramide in cannabinoid action. Moreover, as far as we know, this is also the first report showing that ceramide depresses the VEGF pathway by interfering with VEGF production and VEGFR-2 activation, a notion that is in line with the observation that ceramide analogs prevent VEGF-induced cell survival (51, 52). In the context of the “sphingolipid rheostat” theory (48, 49), the mitogenic sphingolipid sphingosine 1-phosphate would shift the balance toward angiogenesis and tumorigenesis (5, 53), whereas the antiproliferative sphingolipid ceramide would blunt angiogenesis and tumorigenesis (present study).

The use of cannabinoids in medicine is limited by their psychoactive effects mediated by neuronal CB1 receptors (9, 10). Although these adverse effects are within the range of those accepted for other medications, especially in cancer treatment, and tend to disappear with tolerance on continuous use (20), it is obvious that cannabinoid-based therapies devoid of side-effects would be desirable. As glioma cells express functional CB2 receptors (26), we used a selective CB2 ligand to target the VEGF pathway. Selective CB2 receptor activation in mice also inhibits the growth and angiogenesis of skin carcinomas (19). Unfortunately, very little is known about the pharmacokinetics and toxicology of the selective CB2 ligands synthesized to date, making them as yet unavailable for clinical trials.

Gliomas are one of the most malignant forms of cancer, resulting in the death of affected patients within 1–2 years after diagnosis. Current therapies for glioma treatment are usually ineffective or just palliative. Therefore, it is essential to develop new therapeutic strategies for the management of glioblastoma multiforme, which will most likely require a combination of therapies to obtain significant clinical results. In line with the idea that anti-VEGF treatments constitute one of the most promising antitumoral approaches currently available (5–7), the present laboratory and clinical findings provide a novel pharmacological target for cannabinoid-based therapies.

ACKNOWLEDGMENTS

We are indebted to M. A. Muñoz and C. Sánchez for expert technical assistance in the confocal microscopy experiments, Dr. L. García for personal support, and Drs. G. Velasco and I. Galve-Roperh for discussion and advice.

REFERENCES

Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas

Cristina Blázquez, Luis González-Feria, Luis Álvarez, et al.

Cancer Res 2004;64:5617-5623.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/16/5617

Cited articles
This article cites 53 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/16/5617.full#ref-list-1

Citing articles
This article has been cited by 20 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/16/5617.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.